Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.
BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels. AIMS: To investigate whether long-term combination antiretroviral therapy (cART) resto...
| Egile Nagusiak: | , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Journal article |
| Hizkuntza: | English |
| Argitaratua: |
2010
|
| _version_ | 1826302501915197440 |
|---|---|
| author | Rohrbach, J Robinson, N Harcourt, G Hammond, E Gaudieri, S Gorgievski, M Telenti, A Keiser, O Günthard, H Hirschel, B Hoffmann, M Bernasconi, E Battegay, M Furrer, H Klenerman, P Rauch, A |
| author_facet | Rohrbach, J Robinson, N Harcourt, G Hammond, E Gaudieri, S Gorgievski, M Telenti, A Keiser, O Günthard, H Hirschel, B Hoffmann, M Bernasconi, E Battegay, M Furrer, H Klenerman, P Rauch, A |
| author_sort | Rohrbach, J |
| collection | OXFORD |
| description | BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels. AIMS: To investigate whether long-term combination antiretroviral therapy (cART) restores HCV-specific T cell responses and improves the control of HCV replication. METHODS: T cell responses were evaluated longitudinally in 80 HIV/HCV coinfected individuals by ex vivo interferon-gamma-ELISpot responses to HCV core peptides, that predominantly stimulate CD4(+) T cells. HCV RNA levels were assessed by real-time PCR in 114 individuals. RESULTS: The proportion of individuals with detectable T cell responses to HCV core peptides was 19% before starting cART, 24% in the first year on cART and increased significantly to 45% and 49% after 33 and 70 months on cART (p=0.001). HCV-specific immune responses increased in individuals with chronic (+31%) and spontaneously cleared HCV infection (+30%). Median HCV RNA levels before starting cART were 6.5 log(10) IU/ml. During long-term cART, median HCV-RNA levels slightly decreased compared to pre-cART levels (-0.3 log10 IU/ml, p=0.02). CONCLUSIONS: Successful cART is associated with increasing cellular immune responses to HCV core peptides and with a slight long-term decrease in HCV RNA levels. These findings are in line with the favourable clinical effects of cART on the natural history of hepatitis C and with the current recommendation to start cART earlier in HCV/HIV coinfected individuals. |
| first_indexed | 2024-03-07T05:48:30Z |
| format | Journal article |
| id | oxford-uuid:e807a647-6a13-4340-b361-f5f6a072312e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:48:30Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:e807a647-6a13-4340-b361-f5f6a072312e2022-03-27T10:43:39ZCellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e807a647-6a13-4340-b361-f5f6a072312eEnglishSymplectic Elements at Oxford2010Rohrbach, JRobinson, NHarcourt, GHammond, EGaudieri, SGorgievski, MTelenti, AKeiser, OGünthard, HHirschel, BHoffmann, MBernasconi, EBattegay, MFurrer, HKlenerman, PRauch, A BACKGROUND: Hepatitis C virus (HCV) infection is a major cause of morbidity in HIV infected individuals. Coinfection with HIV is associated with diminished HCV-specific immune responses and higher HCV RNA levels. AIMS: To investigate whether long-term combination antiretroviral therapy (cART) restores HCV-specific T cell responses and improves the control of HCV replication. METHODS: T cell responses were evaluated longitudinally in 80 HIV/HCV coinfected individuals by ex vivo interferon-gamma-ELISpot responses to HCV core peptides, that predominantly stimulate CD4(+) T cells. HCV RNA levels were assessed by real-time PCR in 114 individuals. RESULTS: The proportion of individuals with detectable T cell responses to HCV core peptides was 19% before starting cART, 24% in the first year on cART and increased significantly to 45% and 49% after 33 and 70 months on cART (p=0.001). HCV-specific immune responses increased in individuals with chronic (+31%) and spontaneously cleared HCV infection (+30%). Median HCV RNA levels before starting cART were 6.5 log(10) IU/ml. During long-term cART, median HCV-RNA levels slightly decreased compared to pre-cART levels (-0.3 log10 IU/ml, p=0.02). CONCLUSIONS: Successful cART is associated with increasing cellular immune responses to HCV core peptides and with a slight long-term decrease in HCV RNA levels. These findings are in line with the favourable clinical effects of cART on the natural history of hepatitis C and with the current recommendation to start cART earlier in HCV/HIV coinfected individuals. |
| spellingShingle | Rohrbach, J Robinson, N Harcourt, G Hammond, E Gaudieri, S Gorgievski, M Telenti, A Keiser, O Günthard, H Hirschel, B Hoffmann, M Bernasconi, E Battegay, M Furrer, H Klenerman, P Rauch, A Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. |
| title | Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. |
| title_full | Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. |
| title_fullStr | Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. |
| title_full_unstemmed | Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. |
| title_short | Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. |
| title_sort | cellular immune responses to hcv core increase and hcv rna levels decrease during successful antiretroviral therapy |
| work_keys_str_mv | AT rohrbachj cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT robinsonn cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT harcourtg cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT hammonde cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT gaudieris cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT gorgievskim cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT telentia cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT keisero cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT gunthardh cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT hirschelb cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT hoffmannm cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT bernasconie cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT battegaym cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT furrerh cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT klenermanp cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy AT raucha cellularimmuneresponsestohcvcoreincreaseandhcvrnalevelsdecreaseduringsuccessfulantiretroviraltherapy |